<div id="readability-page-1"><div> <div> Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. , /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)'s sale to Biogen Inc. for $41.00 per share in cash and a nontransferable contingent value right for the right to receive two payments of $2.00 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE. If you are an Apellis shareholder, click here to learn more about your legal rights and options. Centessa Pharmaceuticals plc (NASDAQ: CNTA)'s sale to Eli Lilly and Company for $38.00 in cash per share plus one non-transferrable contingent value right entitling the holder to receive up to an aggregate of $9.00 subject to the achievement of certain milestones. If you are a Centessa shareholder, click here to learn more about your legal rights and options. Kezar Life Sciences, Inc. (NASDAQ: KZR)'s sale to Aurinia Pharmaceuticals Inc. for $6.955 in cash per share and one non-transferable contingent value right. If you are a Kezar shareholder, click here to learn more about your legal rights and options. On behalf of shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures and information, or other relief and benefits. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Halper Sadeh LLC Daniel Sadeh, Esq. Zachary Halper, Esq. One World Trade Center 85th Floor New York, NY 10007 (212) 763-0060 [email protected] [email protected] https://www.halpersadeh.com SOURCE Halper Sadeh LLP <img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDEwJk5ld3NJdGVtSWQ9TlkzMTY2MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MTAxMzM0UFJfTkVXU19VU1BSX19fX19OWTMxNjYw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNDEwJk5ld3NJdGVtSWQ9TlkzMTY2MCZUcmFuc21pc3Npb25fSWQ9MjAyNjA0MTAxMzM0UFJfTkVXU19VU1BSX19fX19OWTMxNjYw"/></div> </div></div>

Halper Sadeh LLC is investigating Apellis Pharmaceuticals (APLS), Centessa Pharmaceuticals (CNTA), and Kezar Life Sciences (KZR) for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders due to proposed transaction terms. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost. The investigations focus on the sales of these companies to larger firms, with potential for increased consideration or disclosures sought on behalf of shareholders.

prnewswire

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

VG Health

Health Care Select Sector SPDR

Kezar Life Sciences

Centessa Pharmaceuticals

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

Apellis Pharma

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

VanEck Biotech ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

13:34 ETAre APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?